---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-037176"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:18:35.011346+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology files pro forma financials for Apexigen acquisition; combined net loss $97.8M

## Summary
- Pro forma combined net loss for FY 2023: $97.8M (basic EPS $2.29).
- Purchase price for Apexigen: $10.7M, comprising 4.3M Pyxis shares at $2.295/share.
- Intangible assets acquired: $24.5M (IPR&D $21.0M, royalty rights $3.5M).
- Nonrecurring transaction costs included: $1.7M in Pyxis G&A, $5.5M in Apexigen G&A.
- Severance costs of $4.7M recorded: $1.6M G&A, $3.1M R&D.

## SEC filing metadata
- accession: 0000950170-24-037176
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017024037176/0000950170-24-037176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017024037176/pyxs-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-037176
- JSON: https://secwatch.observer/filing/0000950170-24-037176.json
- Plain text: https://secwatch.observer/filing/0000950170-24-037176.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.